Format
Sort by

Send to

Choose Destination

Selected items

Items: 4

1.

A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.

Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M, Raue F, Ritter MM, Höppner W.

J Clin Endocrinol Metab. 1998 Mar;83(3):770-4.

PMID:
9506724
2.

Genetic testing in pheochromocytoma or functional paraganglioma.

Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoli-Sire P, Richard S, Rohmer V, Sadoul JL, Strompf L, Schlumberger M, Bertagna X, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP.

J Clin Oncol. 2005 Dec 1;23(34):8812-8.

PMID:
16314641
3.

Familial prevalence and age of RET germline mutations: implications for screening.

Machens A, Dralle H.

Clin Endocrinol (Oxf). 2008 Jul;69(1):81-7. Epub 2008 Jul 1.

PMID:
18062802
4.

RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2A syndrome?

Gimm O, Niederle BE, Weber T, Bockhorn M, Ukkat J, Brauckhoff M, Thanh PN, Frilling A, Klar E, Niederle B, Dralle H.

Surgery. 2002 Dec;132(6):952-9; discussion 959.

PMID:
12490841

Supplemental Content

Support Center